Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025
18 avr. 2024 02h00 HE
|
Pharming Group N.V.
NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. ...
Pharming announces completion of enrollment in pediatric clinical trial of leniolisib
08 avr. 2024 01h00 HE
|
Pharming Group N.V.
This multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency Leiden, the Netherlands, April 8, 2024: Pharming...
Pharming Group announces the 2024 Annual General Meeting of Shareholders
04 avr. 2024 02h30 HE
|
Pharming Group N.V.
Leiden, The Netherlands, April 4, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that the Company’s 2024 Annual General Meeting of...
Pharming Group announces the filing of its 2023 Annual Report and Form 20-F
04 avr. 2024 01h00 HE
|
Pharming Group N.V.
Leiden, The Netherlands, April 4, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces the filing of its Annual Report for the year ended...
Pharming Group to participate in April investor conferences
03 avr. 2024 02h00 HE
|
Pharming Group N.V.
Leiden, The Netherlands, April 3, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor...
Pharming Group reports fourth quarter and full year 2023 financial results
14 mars 2024 02h00 HE
|
Pharming Group N.V.
Full year 2023 total revenues increased by 19% to US$245.3 millionRecord fourth quarter RUCONEST® revenues of US$73.3 million resulted in a 10% increase in full year 2023 RUCONEST® revenues to...
Pharming Group to report fourth quarter and full year 2023 financial results on March 14
29 févr. 2024 02h00 HE
|
Pharming Group N.V.
Leiden, The Netherlands, February 29, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year...
Pharming Group to participate in February investor conferences
08 févr. 2024 02h00 HE
|
Pharming Group N.V.
Leiden, The Netherlands, February 8, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor...
Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update
08 janv. 2024 01h00 HE
|
Pharming Group N.V.
Expect 10% growth in RUCONEST® revenue, significantly exceeding prior guidance Expect Joenja® revenues of approximately US$18 million with 81 patients on paid therapy at year end ...
Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)
13 déc. 2023 01h00 HE
|
Pharming Group N.V.
Initial development in PIDs with immune dysregulation linked to PI3Kẟ signaling Phase 2 clinical trial initiation planned for 2Q 2024 Leiden, The Netherlands, December...